Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Weekly paclitaxel vs three‐weekly paclitaxel

Progression‐free survival · women with recurrent epithelial ovarian cancer

It is very uncertain whether weekly paclitaxel changes progression‐free survival compared with three‐weekly paclitaxel (very low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.83 [0.46, 1.52]
2 studies · 263 participants
Very low

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Progression‐free survival · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.89 [0.81, 0.98]
4 studies · 3699 participants
Moderate